| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3990694 | Journal of Thoracic Oncology | 2012 | 11 Pages |
Abstract
Fulvestrant may enhance effects of vandetanib in NSCLC by blocking estrogen-driven activation of the EGFR pathway.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Jill M. PhD, Christopher T. MS, Mary E. BS, Cassandra BS, Laura P. PhD,